This may be relevant for myeloma treatment, because YAP1 is under control of the serine-threonine kinase, STK4, and pharmacological inactivation of STK4 may restore YAP1 levels and, thereby, kill myeloma cells (Figure 3, right). Here, MARK2 is linked to plasma cell myeloma.